Angiogenesis in male breast cancer.
BACKGROUND: Male breast cancer is a rare but aggressive and devastating disease. This disease presents at a later stage and in a more advanced fashion than its female counterpart. The immunophenotype also appears to be distinct when compared to female breast cancer. Angiogenesis plays a permissive role in the development of a solid tumor and provides an avenue for nutrient exchange and waste removal. Recent scrutiny of angiogenesis in female breast cancer has shown it to be of significant prognostic value. It was hypothesized that this holds true in invasive ductal carcinoma of the male breast. In the context of male breast cancer, we investigated the relationship of survival and other clinico-pathological variables to the microvascular density of the tumor tissue. METHODS: Seventy-five cases of primary male breast cancer were identified using the records of the Saskatchewan Cancer Agency over a period of 26 years. Forty-seven cases of invasive ductal carcinoma of the male breast had formalin-fixed paraffin-embedded tissue blocks that were suitable for this study. All cases were reviewed. Immunohistochemical staining was performed for the angiogenic markers (cluster designations 31 (CD31), 34 (CD34) and 105 (CD105), von Willebrand factor (VWF), and vascular endothelial growth factor (VEGF)). Microvascular density (MVD) was determined using average, centre, and highest microvessel counts (AMC, CMC, and HMC, respectively). Statistical analyses compared differences in the distribution of survival times and times to relapse between levels of MVD, tumor size, node status and age at diagnosis. In addition, MVD values were compared within each marker, between each marker, and were also compared to clinico-pathological data. RESULTS: Advanced age and tumor size were related to shorter survival times. There were no statistically significant differences in distributions of survival times and times to relapse between levels of MVD variables. There was no significant difference in MVD between levels of the different clinico-pathological variables. MVD was strongly and significantly correlated between AMC, CMC and HMC for CD31, CD34, and CD105 (p < 0.01) and remained moderate to weak for VWF and VEGF. CONCLUSION: Microvascular density does not appear to be an independent prognostic factor in male breast cancer. However, the likelihood of death for men with breast cancer is increased in the presence of increased age at diagnosis and advanced tumor size. This is perhaps linked to inherent tumor vasculature, which is strongly related throughout a tumor section.
Frangou
Evan M
EM
Department of Pathology, University of Saskatchewan, Royal University Hospital, 103 Hospital Drive, Saskatoon, Canada. inarkanth@shaw.ca.
Lawson
Joshua
J
Kanthan
Rani
R
Annu Rev Biochem. 1998;67:395-424
9759493
J Cell Biol. 1995 Jul;130(2):451-60
7542249
Am J Physiol Cell Physiol. 2001 Jun;280(6):C1367-74
11350731
Eur J Cancer. 1995 Nov;31A(12):1960-4
8562148
Oncogene. 2000 Dec 11;19(53):6122-9
11156525
Cancer. 1999 Feb 1;85(3):629-39
10091736
Science. 1993 Dec 3;262(5139):1580-2
8248808
Hum Pathol. 1995 Nov;26(11):1196-200
7590692
Blood. 1986 Mar;67(3):842-5
3947749
J Exp Med. 1992 May 1;175(5):1401-4
1569405
J Exp Med. 1994 Mar 1;179(3):1059-64
8113674
Am Surg. 1994 Nov;60(11):816-20
7978672
J Exp Med. 1990 Jun 1;171(6):2147-52
2351935
J Invest Dermatol. 1995 Jul;105(1):44-50
7615975
Br J Surg. 1997 Apr;84(4):433-5
9112887
Surg Clin North Am. 1996 Apr;76(2):343-63
8610268
J Biol Chem. 1993 Jul 25;268(21):16037-46
8340425
FASEB J. 2003 Jun;17 (9):984-92
12773481
Toxicol Pathol. 1999 Jan-Feb;27(1):78-86
10367678
Cancer. 1996 Feb 1;77(3):490-8
8630956
Br J Haematol. 1993 Mar;83(3):370-83
7683483
Hum Pathol. 1992 Jul;23(7):755-61
1377162
Anticancer Res. 2001 Nov-Dec;21(6B):4325-31
11908687
Microsc Res Tech. 2003 Feb 1;60(2):186-98
12539173
Br J Cancer. 1995 Jun;71(6):1359-62
7779739
Crit Rev Oncol Hematol. 2001 Feb;37(2):97-114
11166583
J Exp Clin Cancer Res. 2003 Mar;22(1):29-33
12725319
Acta Derm Venereol. 1998 Jan;78(1):19-21
9498020
Cancer. 1994 Aug 15;74(4):1289-93
8055450
Leukemia. 1987 May;1(5):417-26
2444831
Pathol Res Pract. 2000;196(9):607-12
10997734
Prostate Cancer Prostatic Dis. 2002;5(2):123-7
12497001
Blood. 1990 Jun 15;75(12):2417-26
1693532
J Cell Biol. 1991 Sep;114(5):1059-68
1874786
J Exp Med. 1993 Aug 1;178(2):449-60
8340753
Eur J Cancer. 1996 Sep;32A(10):1686-92
8983275
J Lab Clin Med. 1993 Apr;121(4):579-87
8454940
Arch Pathol Lab Med. 2003 Jan;127(1):36-41
12521364
Endocr Rev. 1997 Feb;18(1):4-25
9034784
Vascul Pharmacol. 2002 Nov;39(4-5):225-37
12747962
Blood. 1995 Jun 1;85(11):3150-7
7756647
J Biol Chem. 1996 May 10;271(19):11090-8
8626652
Nat Med. 2003 Jun;9(6):669-76
12778165
Arch Ophthalmol. 1994 Nov;112(11):1476-82
7980139
FASEB J. 2000 Jan;14 (1):55-64
10627280
Int J Cancer. 2000 Mar 20;89(2):122-6
10754488
Breast Cancer Res Treat. 1999 Jan;53(1):19-31
10206069
Eur J Cancer. 1993;29A(8):1141-5
8390846
J Clin Invest. 1997 May 15;99(10):2351-7
9153276
Proc Natl Acad Sci U S A. 1995 Nov 7;92 (23 ):10457-61
7479819
Br J Cancer. 2002 Dec 2;87(12):1422-30
12454772
Cancer Res. 1996 May 1;56(9):2013-6
8616842
Int J Cancer. 2002 Jul 10;100(2):123-30
12115558
J Biol Regul Homeost Agents. 2001 Jan-Mar;15(1):1-13
11388737
Invest Ophthalmol Vis Sci. 1996 Apr;37(5):855-68
8603870
Clin Cancer Res. 2001 Mar;7(3):524-32
11297243
J Cutan Pathol. 1997 Sep;24(8):484-93
9331894
J Biol Chem. 1997 Jul 18;272(29):18007-14
9218428
J Natl Cancer Inst. 1992 Dec 16;84(24):1875-87
1281237
Nature. 1996 Apr 4;380(6573):435-9
8602241
Cancer. 1998 Nov 15;83(10):2139-49
9827718
Nature. 1996 Apr 4;380(6573):439-42
8602242
World J Gastroenterol. 2002 Jun;8(3):385-92
12046056
J Clin Invest. 1985 Sep;76(3):1102-6
2413071
FASEB J. 1990 Aug;4(11):2868-80
2199285
Nat Med. 1999 Jun;5(6):623-8
10371499
J Surg Oncol. 2000 Dec;75(4):252-7
11135266
N Engl J Med. 1995 Dec 28;333(26):1757-63
7491141
Hum Reprod. 1993 Feb;8(2):175-81
8097204
J Cell Sci. 1996 Feb;109 ( Pt 2):437-45
8838667
Gan To Kagaku Ryoho. 2003 May;30(5):599-605
12795089
Stroke. 1996 Oct;27(10):1865-72; discussion 1872-3
8841346
Best Pract Res Clin Haematol. 2001 Jun;14(2):241-55
11686098
Proc Natl Acad Sci U S A. 1979 Oct;76(10):5217-21
291937
Clin Cancer Res. 1995 Dec;1(12 ):1623-34
9815965
J Hematother. 1992 Summer;1(2):115-29
1285404
Surg Oncol. 1993 Dec;2(6):325-33
8130939
Anticancer Res. 1998 Sep-Oct;18(5A):3621-8
9858949
Cancer. 2004 Jul 1;101(1):51-7
15221988
J Clin Invest. 2003 Mar;111(5):707-16
12618525
J Pathol. 1990 Jul;161(3):267-71
2391587
J Biol Chem. 2002 Nov 15;277(46):43799-808
12228247
Cancer. 1998 Aug 1;83(3):498-509
9690543
Lancet. 1992 Jul 18;340(8812):145-6
1378165
Blood. 1996 Jan 1;87(1):67-72
8547678
Surg Clin North Am. 2003 Feb;83(1):61-75
12691450
Cancer Res. 1999 Feb 15;59(4):856-61
10029075
Hum Pathol. 1995 Jan;26(1):86-91
7821921
J Biol Chem. 1985 Sep 15;260(20):11300-6
3161894
Proc Natl Acad Sci U S A. 1974 May;71(5):1906-9
4209883
N Engl J Med. 1991 Jan 3;324(1):1-8
1701519
J Immunol. 1996 Feb 15;156(4):1515-24
8568255
Ann Surg Oncol. 1997 Jul-Aug;4(5):385-8
9259964
Lab Invest. 1990 Jun;62(6):690-6
1694254